Oxford Gene Technology (OGT), provider of molecular genetics solutions, is presenting a workshop titled “An Integrated Genomic Approach to Tumor Profiling” today at the Association for Molecular Pathology (AMP) annual meeting in National Harbor, MD.
Research into the identification of clinically relevant genetic mutations is growing rapidly; however, the complexity of genomic variation means that the use of multiple technologies is often required to obtain a complete understanding of a given disease. James Clough, Executive Vice President Commercial, and Ephrem Chin, Business Development Manager, for OGT, are exploring how next generation sequencing (NGS), microarrays, and fluorescence in situ hybridisation (FISH) can be combined to present a fully comprehensive, integrated approach and meet this growing need.
As NGS becomes more affordable, targeted sequencing provides an accurate, high-resolution approach to mutation detection. OGT representatives are telling conference attendees how OGT’s SureSeq Solid Tumor Panel, developed in collaboration with recognized cancer experts, covers all exons of key genes for a range of cancer types including breast, prostate, ovarian, lung, and colorectal—enabling detection and discovery of both known and novel variants. For detecting copy number variations (CNVs), they explain that array comparative genomic hybridization (aCGH) is still the gold standard, and OGT’s CytoSure Cancer +SNP Arrays also provide the facility to uncover loss of heterozygosity (LOH) information. For certain aberrations such as translocations, FISH remains the most reliable mainstream technology, and it is the final piece of this genomic puzzle that is being explored in OGT’s workshop.
Attendees of the workshop will hear how the latest genomic technologies are being applied together to comprehensively characterize genetic abnormalities for accelerating cancer research. Learn more about NGS products, array products, FISH probes, and genomic services provided by OGT.Read more